Welcome to our dedicated page for National Health SEC filings (Ticker: NHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The National HealthCare Corporation (NHC) SEC filings page provides access to the company’s regulatory disclosures as a NYSE American issuer. NHC’s common stock, with a par value of $0.01 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades under the symbol NHC. Through its affiliates, the company operates skilled nursing facilities, assisted living and independent living communities, behavioral health hospitals, homecare agencies, and hospice agencies, along with Alzheimer’s and memory care units, pharmacy services, a rehabilitation services company, and management and accounting services to third party post-acute operators.
In its Form 8-K current reports, NHC discloses material events such as quarterly and annual earnings releases, dividend declarations, and significant lease and governance matters. For example, the company files 8-Ks to furnish earnings press releases for periods ended March 31, June 30, September 30, and December 31, and to announce quarterly common dividends. These filings often reference non-GAAP financial measures and include or incorporate reconciliations to GAAP results.
NHC’s 8-K filings also describe corporate governance and executive changes, including the appointment of new directors, committee assignments, and planned retirements of senior officers, as well as role changes for executives. Additional 8-Ks address lease arrangements, such as disclosures about a master lease with National Health Investors, Inc., letters alleging non-monetary non-compliance, cure periods, renewal options, and the potential for a material adverse impact on NHC’s financial position and results of operations if certain lease rights were lost.
On this page, users can review NHC’s SEC reports as they are made available through EDGAR and use AI-powered summaries to understand the key points in lengthy filings. These tools can help clarify topics such as segment reporting for inpatient services and home care hospice services, dividend practices, lease terms and disputes, and board and executive leadership changes, without replacing the full text of the official documents.
National HealthCare Corp. (NHC) reported an insider transaction by its SVP, CFO. On 11/11/2025, the officer exercised 4,000 stock options at $94.10 per share (Code M). To cover the exercise price and withholding taxes, 3,224 shares were withheld (Code F). Following these transactions, the officer directly owned 24,490 shares of common stock.
Remaining derivative holdings include options with exercise prices of $53.94 (8,000 shares outstanding), $94.10 (8,000 shares remaining from a 12,000 grant), and $90.62 (13,500 shares), with expirations between 2028 and 2030 as disclosed.
National Healthcare Corp. (NHC) CEO and director Stephen Flatt reported insider transactions on 11/11/2025. He exercised 3,000 options at $94.10 per share (code M) and the company withheld 2,480 shares to cover the exercise price and taxes (code F). Following these transactions, he beneficially owns 60,130 common shares.
Outstanding equity awards listed include options expiring on 03/08/2028 at $53.94 (8,000 shares), on 03/05/2029 at $94.10 (10,000 shares after the exercise), and on 02/28/2030 at $90.62 (18,000 shares).
National HealthCare Corp. (NHC) director Emil E. Hassan reported an open-market sale of 5,500 shares of common stock at $133 per share on 11/12/2025. Following the transaction, he beneficially owns 73,095 shares directly.
The filing also lists multiple director option awards of 7,500 shares per grant, including examples with exercise prices of $71.64 and $96.03, with stated exercisable and expiration dates. A note clarifies that an option previously shown as [2024 Grant] was corrected here to [2025 Grant].
National HealthCare Corporation announced board and leadership updates. On November 6, 2025, the Board appointed Dr. Lisa Piercey as a Class 1 independent director and named her to the Audit Committee. She will be a nominee for a three‑year term at the 2026 Annual Meeting and will receive standard non‑employee director compensation. She will also enter into the company’s standard director and officer indemnification agreement.
The company confirmed succession steps tied to the previously announced retirement of President and COO R. Michael Ussery effective December 31, 2025. CEO Stephen F. Flatt will also serve as President upon Mr. Ussery’s retirement, with no compensation changes approved at this time. Timothy J. Shelly, SVP Operations, will assume the role of principal operating officer following the retirement. A press release regarding the new director was furnished as Exhibit 99.1.
National HealthCare Corporation (NHC) filed an 8-K under “Other Events” disclosing that the company issued a press release on November 6, 2025 announcing its quarterly common dividend. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The filing also notes that NHC’s common stock trades on the NYSE American under the symbol NHC. Investors can review dividend specifics in the attached Exhibit 99.1.
National HealthCare Corporation (NHC) furnished an 8-K to announce it issued a press release covering its earnings for the period ended September 30, 2025. The full press release is provided as Exhibit 99.1, with the cover page Inline XBRL embedded as Exhibit 104. NHC’s common stock trades on the NYSE American under the symbol NHC.
National HealthCare Corporation (NHC) reported higher third‑quarter revenue and solid cash generation. Net operating revenues were $382.7 million, up from $340.2 million a year ago, driven by inpatient services ($331.3 million) and homecare and hospice ($39.6 million). Net income attributable to NHC was $39.2 million versus $42.8 million last year; diluted EPS was $2.50 compared with $2.73. Results included $20.8 million of unrealized gains on marketable equity securities.
For the first nine months, revenue was $1.13 billion versus $938.0 million last year, with operating income rising to $95.2 million from $61.0 million. Operating cash flow reached $168.3 million, supporting debt reduction to $73.1 million from $137.0 million and higher cash of $130.6 million versus $76.1 million at year‑end. The company repurchased 88,738 shares for $9.6 million year‑to‑date and declared dividends of $0.64 per share in the quarter ($1.89 year‑to‑date). Shares outstanding were 15,515,110 as of September 30, 2025, and 15,515,253 as of November 3, 2025.
BlackRock, Inc. filed a Schedule 13G/A (Amendment No. 7) disclosing beneficial ownership of 1,800,345 shares of National Healthcare Corp (NHC) common stock, representing 11.6% of the class as of the event date 09/30/2025.
BlackRock reports sole voting power over 1,770,601 shares and sole dispositive power over 1,800,345 shares. The filing certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Item 6 notes various persons have rights to dividends or sale proceeds from these securities, and no single person’s interest exceeds five percent of total outstanding common shares.
National Healthcare Corporation (NHC) disclosed that R. Michael Ussery, its President and Chief Operating Officer, informed the company on September 23, 2025 that he will retire effective December 31, 2025. Mr. Ussery has been with NHC since 1980 and has held roles including Senior Vice President-Operations, Senior Vice President-Central Region, Regional Vice President and multiple facility Administrator positions; he was named Administrator of the Year in 1989. He became Chief Operating Officer on January 1, 2009 and was appointed President on January 1, 2017, and will continue serving in both roles through his retirement. The company furnished a press release dated September 26, 2025 as Exhibit 99.1.
Robert G. Adams, a director of National HealthCare Corp (NHC), exercised options and acquired shares on 09/19/2025. He exercised 4,500 options from a 2021 grant at an exercise price of $71.64, resulting in the acquisition of 4,500 shares reported as an acquisition at $71.64 per share.
The filing shows Mr. Adams beneficially owns 13,579 shares following the transaction through a trust and holds indirect interests through a partnership position of 430,341 shares as general partner. The report also lists outstanding options granted in 2022, 2023, 2024 and 2025, each for 7,500 shares, with varying exercise prices and expiration dates.
FAQ
What is the current stock price of National Health (NHC)?
What is the market cap of National Health (NHC)?
